Evidence map›Paper›PMID 40875274›Full record

ArticleRadiation protection dosimetry2025

Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide.

Nishte Rassol, Charlotte Ytterbrink, Daniella Pettersson, Amin Al-Awar, Hana Bakr, Magnus Gram, Johan Spetz, Eva Forssell-Aronsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation protection dosimetry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nishte RassolDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.ORCID 0009-0005-2982-3275
Charlotte YtterbrinkDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
Daniella PetterssonDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
Amin Al-AwarDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
Hana BakrDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
Magnus GramPaediatrics, Department of Clinical Sciences Lund, Lund University, SE-221 85 Lund, and Department of Neonatology, Skåne University Hospital, SE-221 84 Lund, Sweden.ORCID 0000-0002-5880-2925
Johan SpetzDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
Eva Forssell-AronssonDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden.ORCID 0000-0002-7558-4368

Funding

ALF-agreement ALFGBG-966074Swedish Cancer Society 20 1293Swedish Cancer Society 23 2975Swedish Research Council 2021-02636
6 · The paper itself

Abstract

Late radiation-induced kidney toxicity limits molecular radionuclide therapy using radiopharmaceuticals such as 177Lu-octreotate and 177Lu-octreotide. Better kidney protection would allow higher amounts of radiopharmaceutical to be administered. Coadministration of recombinant human alpha-1-microglobulin (rA1M) has been suggested to protect kidneys from exposure from 177Lu-octreotate. Furthermore, early responding biomarkers are needed that identify patients that should or should not receive higher radiopharmaceutical activity. The aim of this study was to evaluate effects of different administration schedules of rA1M in combination with 177Lu-octreotide on urinary levels of retinol-binding protein 4 (RBP4) and creatinine (Cr). Mice received 60 MBq 177Lu-octreotide intravenously, plus none, one, or several rA1M injections. Urinary RBP4 and Cr concentrations were measured after 6-10 weeks. Urinary RBP4 was similar in all groups, but with large individual variations in some groups. RBP4/Cr may be a useful early-responding biomarker. Further investigations are needed to determine effects of long-term kidney protection by rA1M schedules.

Indexed as

KidneyKidney DiseasesOctreotideRadiation InjuriesRadiation-Protective AgentsRadiopharmaceuticalsAlpha-GlobulinsAnimalsBiomarkersCreatinineDrug Administration ScheduleFemaleHumansMaleMiceRadioisotopesalpha-1-microglobulinAlpha-GlobulinsBiomarkersCreatinineOctreotideRadiation-Protective AgentsRadioisotopesRadiopharmaceuticalsRecombinant Proteins

Identifiers

PMID40875274
PMCPMC12392891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.